GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a significant drop in short interest in June. As of June 15th, there was short interest totaling 271,752 shares, a drop of 53.5% from the May 31st total of 584,471 shares. Currently, 7.9% of the shares of the stock are short sold. Based on an average trading volume of 1,155,944 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Investors Weigh In On GeoVax Labs

Several institutional investors and hedge funds have recently bought and sold shares of GOVX. Jane Street Group LLC bought a new stake in shares of GeoVax Labs in the 1st quarter worth approximately $27,000. HRT Financial LP bought a new position in shares of GeoVax Labs during the fourth quarter valued at approximately $31,000. Hudson Bay Capital Management LP purchased a new stake in GeoVax Labs in the third quarter worth $47,000. Renaissance Technologies LLC bought a new stake in GeoVax Labs in the fourth quarter valued at $104,000. Finally, Armistice Capital LLC bought a new stake in GeoVax Labs in the third quarter valued at $253,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. D. Boral Capital reaffirmed a “hold” rating on shares of GeoVax Labs in a research note on Thursday, April 16th. Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $150.00.

GeoVax Labs Price Performance

GOVX traded down $0.01 during trading on Tuesday, hitting $1.27. 133,593 shares of the stock traded hands, compared to its average volume of 2,649,703. The firm has a market capitalization of $4.41 million, a P/E ratio of -0.07 and a beta of 3.62. The firm has a 50-day moving average of $1.63 and a 200 day moving average of $2.56. GeoVax Labs has a 12-month low of $0.96 and a 12-month high of $23.10.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Wednesday, April 15th. The company reported $1.85 earnings per share (EPS) for the quarter. As a group, equities analysts predict that GeoVax Labs will post -8.69 EPS for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.